|
|
3033 Campus Drive
Plymouth, MN 55442-21 USA
phone:+1 763 398 7000
fax:+1 763 398 7200
|
|
| Symbol |
EVVV |
| Exchange |
Nasdaq |
| Founded |
2000 |
| Employees |
880 |
|
|
| www.ev3.net
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Edovascular technologies for interventional radiology, cardiology, and neurology therapies. |
|
| Management |
| Robert J. Palmisano, President and Chief Executive Officer; Pascal E.R. Girin, Executive Vice President and Chief Operating Officer; Shawn T. McCormick, Senior Vice President, Chief Financial Officer; Stacy Enxing Seng, Executive Vice President and President of Worldwide Peripheral Vascular; Kevin M. Klemz, Senior Vice President, Secretary and Chief Legal Officer |
| |
|
|
|
|
|
|
| Recent Results |
| Net sales increased 52.6% to $42.2 million in the three months ended April 2, 2006, compared to $27.7 million in the three months ended April 3, 2005, primarily as a result of continued improvements in sales force productivity and increased market penetration of products introduced during the past 18 months. ev3's net loss for the 3 months ended April 2 was $24.5 million, down 24% year-to-year. ev3 has lowered its annual net sales guidance range to $196 to $208 million, representing net sales growth targets ranging from 47% to 56% over 2005. The previous net sales range was $200 to $220 million. ev3 expects its net sales in the second quarter to be in the range of $45 to $49 million, representing growth rates of 43% to 55% over the second quarter of 2005. |
| |
|
|
|
|
| Keywords |
| endovascular, embolization, thrombectomy, neuroradiologists, hemorrhagic |
|
|
|
| Description |
|
ev3 designs, manufactures and distributes catheter-based, or endovascular, technologies for the minimally invasive treatment of vascular diseases and disorders. |
|
| Products / Services |
ev3's broad product portfolio is focused on applications in each of the three sub-markets of the endovascular device market: peripheral vascular, cardiovascular and neurovascular. Products presently include guidewires, snares, thrombectomy systems, embolic protection devices, infusion catheters/wires and a range of peripheral vascular, bronchial and biliary stent systems.
|
|
| Market / Customers |
ev3's cardio peripheral segment contains products used in both cardiovascular and peripheral vascular procedures by cardiologists, radiologists and vascular surgeons. Its neurovascular segment contains products used primarily by neuro-radiologists and neurosurgeons.
|
|
| Strategy |
In January 2006, ev3 acquired all public shares of Micro Therapeutics, Inc., (MTI), making MTI a wholly owned subsidiary.
|
|
| Funding |
| ev3 completed an initial public offering in June 2005. Cash, cash equivalents and short-term investments available to fund current operations were $56 million at April 2, 2006. |
|
| Status |
| ev3 introduced two new products in the first quarter 2006 and expects to introduce additional new products during the remainder of 2006. |
|
|
Additional Information |
| The company believes the overall market for endovascular devices will grow as the demand for minimally invasive treatment of vascular diseases and disorders continues to increase. ev3 intends to capitalize on this market opportunity through the continued |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members